Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study was conducted in subjects with psoriasis to evaluate drug activity in this patient population by analysis of changes in psoriatic lesion biopsy characteristics. This subject population was selected to evaluate potentially relevant biological activity of CP-690,550 as well as assessing safety and pharmacokinetics.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 5 mg BID | Experimental | 5 mg BID for 13 days and once on Day 14 |
|
| 10 mg BID | Experimental | 10 mg BID for13 days and once on Day 14* |
|
| 20 mg BID | Experimental | 20 mg BID for 13 days and once on Day 14 |
|
| 30 mg BID | Experimental | 30 mg BID for 13 days and once on Day 14 |
|
| 60 mg QD | Experimental | 60 mg QD for 14 days |
|
| 50 mg BID | Experimental | 50 mg BID x 13 days and once on day 14 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| tofacitinib | Drug | 5 mg BID For 13 days and once on Day 14 |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 1 | Triplicate 12-lead electrocardiogram (ECG) measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. For each scheduled hour post morning dose (HPD), except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD. | 23 hours (hrs) prior to morning dose on Day 1 (Baseline for HPD 1), 1 hour (hr) post morning dose on Day 1 |
| Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 1 | Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. For each scheduled hour post morning dose (HPD), except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD. | 22 hrs prior to morning dose on Day 1 (Baseline for HPD 2), 2 hrs post morning dose on Day 1 |
| Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 1 | Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD. | 20 hrs prior to morning dose on Day 1 (Baseline for HPD 4), 4 hrs post morning dose on Day 1 |
| Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 1 | Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14 | Modified Psoriasis Area and Severity Index (mPASI) assessed lesion severity but not the body surface area affected. Severity was estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final mPASI = sum of the each component scores. Total score range 0-12 , higher score indicated more severity. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Little Rock | Arkansas | 72202 | United States |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | CP-690,550 5 mg (Cohort 1) | CP-690,550 5 milligram (mg) oral powder for constitution (OPC) twice daily for 13 days and single oral dose on Day 14. |
| FG001 | CP-690,550 10 mg (Cohort 2) | CP-690,550 10 mg OPC twice daily for 13 days and single oral dose on Day 14. |
| FG002 | CP-690,550 20 mg (Cohort 3) | CP-690,550 20 mg OPC twice daily for 13 days and single oral dose on Day 14. |
| FG003 | CP-690,550 30 mg (Cohort 4) | CP-690,550 30 mg OPC twice daily for 13 days and single oral dose on Day 14. |
| FG004 | CP-690,550 60 mg (Cohort 5) | CP-690,550 60 mg tablets orally once daily up to Day 14. |
| FG005 | CP-690,550 50 mg (Cohort 6) | CP-690,550 50 mg tablets orally twice daily for 13 days and single oral dose on Day 14. |
| FG006 | Placebo | Placebo matched to CP-690,550 for 13 days and single oral dose on Day 14. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | CP-690,550 5 mg (Cohort 1) | CP-690,550 5 milligram (mg) oral powder for constitution (OPC) twice daily for 13 days and single oral dose on Day 14. |
| BG001 | CP-690,550 10 mg (Cohort 2) |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 1 | Triplicate 12-lead electrocardiogram (ECG) measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. For each scheduled hour post morning dose (HPD), except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD. | Analysis population included all participants who met the eligibility criteria. | Posted | Mean | Standard Deviation | millisecond (msec) | 23 hours (hrs) prior to morning dose on Day 1 (Baseline for HPD 1), 1 hour (hr) post morning dose on Day 1 |
|
Not provided
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | CP-690,550 5 mg (Cohort 1) | CP-690,550 5 milligram (mg) oral powder for constitution (OPC) twice daily for 13 days and single oral dose on Day 14. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Atrial fibrillation | Cardiac disorders | COSTART | Non-systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Headache | General disorders | COSTART | Non-systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Pfizer ClinicalTrials.gov Call Center | Pfizer, Inc. | 1-800-718-1021 | ClinicalTrials.gov_Inquiries@pfizer.com |
Not provided
| ID | Term |
|---|---|
| D011565 | Psoriasis |
| D058225 | Plaque, Amyloid |
| ID | Term |
|---|---|
| D017444 | Skin Diseases, Papulosquamous |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D020763 | Pathological Conditions, Anatomical |
Not provided
Not provided
| ID | Term |
|---|---|
| C479163 | tofacitinib |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| tofacitinib |
| Drug |
10 mg BID for 13 days and once on Day 14* |
|
| tofacitinib | Drug | 20 mg BID for 13 days and once on Day 14 |
|
| tofacitinib | Drug | 30 mg BID for 13 days and once on Day 14 |
|
| tofacitinib | Drug | 60 mg tablet once a day (QD) for 14 days |
|
| tofacitinib | Drug | 50 mg tablets two times a day (BID) for 13 days and once on day 14 |
|
| 16 hrs prior to morning dose on Day 1 (Baseline for HPD 8), 8 hrs post morning dose on Day 1 |
| Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 1 | Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD. | 12 hrs prior to morning dose on Day 1 (Baseline for HPD 12), 12 hrs post morning dose on Day 1 |
| Change From Baseline in QT Interval at 16 Hour Post Morning Dose (HPD 16) on Day 1 | Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.Change from baseline in QT interval at HPD 16 was planned to be analyzed for participants who received CP-690,550 60 mg and matching placebo. | 8 hrs prior to morning dose on Day 1 (Baseline for HPD 16), 16 hrs post morning dose on Day 1 |
| Change From Baseline in QT Interval at 0 Hour Post Morning Dose (HPD 0) on Day 14 | Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. The mean of the triplicates at HPD=0 on Day 1 will be defined as the baseline for HPD=0. | Hour 0 (pre-dose) on Day 1 (Baseline for HPD 0), 0 hr on Day 14 |
| Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 14 | Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD. | 23 hrs prior to morning dose on Day 1 (Baseline for HPD 1), 1 hr post morning dose on Day 14 |
| Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 14 | Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD. | 22 hrs prior to morning dose on Day 1 (Baseline for HPD 2), 2 hrs post morning dose on Day 14 |
| Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 14 | Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD. | 20 hrs prior to morning dose on Day 1 (Baseline for HPD 4), 4 hrs post morning dose on Day 14 |
| Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 14 | Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD. | 16 hrs prior to morning dose on Day 1 (Baseline for HPD 8), 8 hrs post morning dose on Day 14 |
| Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 14 | Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD. | 12 hrs prior to morning dose on Day 1 (Baseline for HPD 12), 12 hrs post morning dose on Day 14 |
| Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval | Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum increase from baseline of 30 to less than (<) 60 msec(borderline) and greater than or equal to (>=) 60 msec (prolonged) were summarized. | 1, 2, 4, 8, 12 hrs post dose, additional 16 hrs post dose for 60 mg once daily group on Day 1; 1, 2 hrs post dose on Day 4, 7, 10;1,2,4,8,12 hrs post dose on Day 14; Day 21 |
| Number of Participants With Corrected QT (QTc) Interval Greater Than or Equal to 500 Millisecond | Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum QTc >=500 msec were reported. | 1, 2, 4, 8, 12 hrs post dose, additional 16 hrs post dose for 60 mg once daily group on Day 1; 1, 2 hrs post dose on Day 4, 7, 10;1,2,4,8,12 hrs post dose on Day 14; Day 21 |
| Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 1 | AUCtau = area under the curve from time zero to end of dosing interval. | 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1 |
| Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 14 | AUCtau = area under the curve from time zero to end of dosing interval. | 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 14 |
| Maximum Observed Plasma Concentration (Cmax) at Day 1 | 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1 |
| Maximum Observed Plasma Concentration (Cmax) at Day 14 | 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 14 |
| Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 1 | 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1 |
| Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 14 | 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 14 |
| Accumulation Ratio (R0) | Accumulation ratio was calculated as, R0 = area under the curve from time zero to end of dosing interval (AUCtau) on Day 14 divided by area under the curve from time zero to end of dosing interval (AUCtau) on Day 1. | 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1 and Day 14 |
| Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1 | Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1. | Baseline, 1 hr post-dose on Day 1 |
| Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2 | Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1. | Baseline, hr 0 on Day 2 |
| Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4 | Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1. | Baseline, hr 0 on Day 4 |
| Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7 | Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1. | Baseline, hr 0 on Day 7 |
| Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10 | Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1. | Baseline, hr 0 on Day 10 |
| Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14 | Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1. | Baseline; hr 0, 8 hr post-dose on Day 14 |
| Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18 | Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1. | Baseline, Hour 0 on Day 18 |
| Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21 | Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1. | Baseline, hr 0 on Day 21 |
| Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28 | Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1. | Baseline, hr 0 on Day 28 |
| Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42 | Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1. | Baseline, hr 0 on Day 42 |
| Change From Baseline in Immune Cell Function at Day 14 | The degree of immunosuppression induced by the study drug administration was evaluated using a bioluminescent assay in which the concentration of Adenosine-5-Triphosphate (ATP) released by CD4 cells was measured. ATP concentrations released from stimulated and unstimulated cells were evaluated. ATP Concentration less than or equal to (<=) 225: low immune cell response, 226 to 524: Moderate immune cell response, >= 525: strong immune cell response. Baseline was defined as the mean of the samples collected during the pre-dose biopsy. | Baseline (Within 7 days prior to Day 1), Day 14 |
| Change From Baseline in Reticulocyte Count at Day 2 | Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis. | Baseline (Within 7 days prior to Day 1), Day 2 |
| Change From Baseline in Reticulocyte Count at Day 4 | Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis. | Baseline (Within 7 days prior to Day 1), Day 4 |
| Change From Baseline in Reticulocyte Count at Day 7 | Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis. | Baseline (Within 7 days prior to Day 1), Day 7 |
| Change From Baseline in Reticulocyte Count at Day 10 | Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis. | Baseline (Within 7 days prior to Day 1), Day 10 |
| Change From Baseline in Reticulocyte Count at Day 15 | Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis. | Baseline (Within 7 days prior to Day 1), Day 15 |
| Change From Baseline in Reticulocyte Count at Day 21 | Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis. | Baseline (Within 7 days prior to Day 1), Day 21 |
| Change From Baseline in Reticulocyte Count at Day 28 | Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis. | Baseline (Within 7 days prior to Day 1), Day 28 |
| Change From Baseline in Reticulocyte Count at Day 42 | Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis. | Baseline (Within 7 days prior to Day 1), Day 42 |
| Time to Reach Maximum Change From Baseline and Time to Return to Baseline Value for Fluorescence-Activated Cell Sorting (FACS), Reticulocyte Counts and Immune Cell Function | Day 0 (pre-dose), 1, 2, 4, 7, 10, 14, 15, 18, 21, 28, 42 |
| Half Maximal Effective Area Under the Concentration-Time Curve 50 (EAUC 50) | EAUC 50 was calculated from a regression analyses using area under the concentration-time curve (AUC) as the independent variable. A sigmoid maximum effect (Emax) model was used to explain the relationship between AUC and modified Psoriasis Severity Index (mPASI) score, where Emax was the maximum effect (100 percent reduction in the total mPASI score from baseline), and EAUC 50 was the AUC where 50 percent of the maximum effect was measured. | Day 14 |
| Baseline (Within 7 days prior to Day 1) up to Day 14 |
| Number of Participants With Physician's Global Assessment (PGA) of Psoriasis | Physician global assessment (PGA) of Psoriasis is a 7-point scale used to assess severity of psoriatic plaques, scaling and/or erythema. Severity scale ranged from 1 to 7: 1=severe, 2=moderate to severe, 3=moderate, 4=mild to moderate, 5=mild, 6=almost clear, 7=clear (no sign of psoriasis). | Baseline (Within 7 days prior to Day 1) up to Day 14 |
| Gene Expression in Psoriatic Plaque Biopsies | Gene expression by quantitative polymerized chain reaction (PCR) using standard curve (SC) method generated by linear regression using log threshold cycle versus log(cell number). Keratin (K)-16, inducible nitric oxide synthase (iNOS), Interleukin 8 (IL-8), CD25, Granzyme B, IL-2, IL-7, IL-15, Interferon-gamma (INF-gamma), C-X-C motif chemokine(CXCL10), perforin 1, B-cell Lymphoma 2 (BCL-2), BCL2 associated X Protein (BAX), Tumor Necrosis Factor Fas Ligand (TNF-FasL), and proliferating cell nuclear antigen (PCNA) presented as control gene normalized expression (relative expression) within SC. | Day 14 |
| Immunohistochemistry From Psoriatic Plaque Biopsies | Immunohistochemical staining of skin biopsies was performed with monoclonal antibodies directed against cluster of differentiation 3 (CD3) and cluster of differentiation 8 (CD8) T-lymphocytes, cluster of differentiation 16/56 (CD16/56) natural killer cells, and cluster of differentiation 83 (CD83) mature dendritic cells. Baseline was defined as mean of samples obtained at the screening visit within 7 days prior to Day 1, at the baseline biopsy, and Day 0. Immunohistochemistry results were planned to be analyzed for participants who received CP-690,550 5, 20, 30 mg and matching placebo. | Baseline (within 7 days prior to Day 1), Day 14 |
| Number of Participants With Keratin 16 (K16) Expression | Immunohistochemical staining of skin biopsies was performed with monoclonal antibodies directed against K16. Number of participants with K16 expression were assessed qualitatively using suprabasal keratinocytes. | Baseline (within 7 days prior to Day 1) up to Day 14 |
| Number of Participants With Intracellular Adhesion Molecule (ICAM-1) by Epidermal Keratinocytes Expression | Immunohistochemical staining of skin biopsies was performed with monoclonal antibodies directed against ICAM-1. Number of participants with ICAM-1 expression was to be assessed qualitatively using epidermal keratinocytes. | Baseline (within 7 days prior to Day 1) up to Day 14 |
| Gene Expression in Peripheral Blood | Punch biopsy and serum blood were assayed for messenger Ribonucleic acid (mRNA) gene expression by quantitative PCR using standard curve(SC) method generated by linear regression using log threshold cycle versus log(cell number). granzyme B, IFN-gamma, TNF-alpha (FasL and superfamily member 5 [SF5]), BCL2, BAX, iNOS, and CD 25 presented as control gene normalized expression(relative expression) within SC. The Relative mRNA Gene Expression Level is relative to baseline and normalized to the housekeeping gene 18 Svedberg unit ribosomal RNA (18S rRNA). | Day 14 |
CP-690,550 10 mg OPC twice daily for 13 days and single oral dose on Day 14.
| BG002 | CP-690,550 20 mg (Cohort 3) | CP-690,550 20 mg OPC twice daily for 13 days and single oral dose on Day 14. |
| BG003 | CP-690,550 30 mg (Cohort 4) | CP-690,550 30 mg OPC twice daily for 13 days and single oral dose on Day 14. |
| BG004 | CP-690,550 60 mg (Cohort 5) | CP-690,550 60 mg tablets orally once daily up to Day 14. |
| BG005 | CP-690,550 50 mg (Cohort 6) | CP-690,550 50 mg tablets orally twice daily for 13 days and single oral dose on Day 14. |
| BG006 | Placebo | Placebo matched to CP-690,550 for 13 days and single oral dose on Day 14. |
| BG007 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| OG001 | CP-690,550 10 mg (Cohort 2) | CP-690,550 10 mg OPC twice daily for 13 days and single oral dose on Day 14. |
| OG002 | CP-690,550 20 mg (Cohort 3) | CP-690,550 20 mg OPC twice daily for 13 days and single oral dose on Day 14. |
| OG003 | CP-690,550 30 mg (Cohort 4) | CP-690,550 30 mg OPC twice daily for 13 days and single oral dose on Day 14. |
| OG004 | CP-690,550 60 mg (Cohort 5) | CP-690,550 60 mg tablets orally once daily up to Day 14. |
| OG005 | CP-690,550 50 mg (Cohort 6) | CP-690,550 50 mg tablets orally twice daily for 13 days and single oral dose on Day 14. |
| OG006 | Placebo | Placebo matched to CP-690,550 for 13 days and single oral dose on Day 14. |
|
|
| Primary | Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 1 | Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. For each scheduled hour post morning dose (HPD), except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD. | Analysis population included all participants who met the eligibility criteria. | Posted | Mean | Standard Deviation | msec | 22 hrs prior to morning dose on Day 1 (Baseline for HPD 2), 2 hrs post morning dose on Day 1 |
|
|
|
| Primary | Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 1 | Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD. | Analysis population included all participants who met the eligibility criteria. Here, the 'n' is signifying those participants who were evaluable for this measure at the specified time point for each arm group. | Posted | Mean | Standard Deviation | msec | 20 hrs prior to morning dose on Day 1 (Baseline for HPD 4), 4 hrs post morning dose on Day 1 |
|
|
|
| Primary | Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 1 | Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD. | Analysis population included all participants who met the eligibility criteria. Here, the 'n' is signifying those participants who were evaluable for this measure at the specified time point for each arm group. | Posted | Mean | Standard Deviation | msec | 16 hrs prior to morning dose on Day 1 (Baseline for HPD 8), 8 hrs post morning dose on Day 1 |
|
|
|
| Primary | Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 1 | Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD. | Analysis population included all participants who met the eligibility criteria. Here, the 'n' is signifying those participants who were evaluable for this measure at the specified time point for each arm group. | Posted | Mean | Standard Deviation | msec | 12 hrs prior to morning dose on Day 1 (Baseline for HPD 12), 12 hrs post morning dose on Day 1 |
|
|
|
| Primary | Change From Baseline in QT Interval at 16 Hour Post Morning Dose (HPD 16) on Day 1 | Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.Change from baseline in QT interval at HPD 16 was planned to be analyzed for participants who received CP-690,550 60 mg and matching placebo. | Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. | Posted | Mean | Standard Deviation | msec | 8 hrs prior to morning dose on Day 1 (Baseline for HPD 16), 16 hrs post morning dose on Day 1 |
|
|
|
| Primary | Change From Baseline in QT Interval at 0 Hour Post Morning Dose (HPD 0) on Day 14 | Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. The mean of the triplicates at HPD=0 on Day 1 will be defined as the baseline for HPD=0. | Analysis population included all participants who met the eligibility criteria. | Posted | Mean | Standard Deviation | msec | Hour 0 (pre-dose) on Day 1 (Baseline for HPD 0), 0 hr on Day 14 |
|
|
|
| Primary | Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 14 | Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD. | Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. | Posted | Mean | Standard Deviation | msec | 23 hrs prior to morning dose on Day 1 (Baseline for HPD 1), 1 hr post morning dose on Day 14 |
|
|
|
| Primary | Change From Baseline in QT Interval at 2 Hour Post Morning Dose (HPD 2) on Day 14 | Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD. | Analysis population included all participants who met the eligibility criteria.'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. | Posted | Mean | Standard Deviation | msec | 22 hrs prior to morning dose on Day 1 (Baseline for HPD 2), 2 hrs post morning dose on Day 14 |
|
|
|
| Primary | Change From Baseline in QT Interval at 4 Hour Post Morning Dose (HPD 4) on Day 14 | Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD. | Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. | Posted | Mean | Standard Deviation | msec | 20 hrs prior to morning dose on Day 1 (Baseline for HPD 4), 4 hrs post morning dose on Day 14 |
|
|
|
| Primary | Change From Baseline in QT Interval at 8 Hour Post Morning Dose (HPD 8) on Day 14 | Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD. | Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. | Posted | Mean | Standard Deviation | msec | 16 hrs prior to morning dose on Day 1 (Baseline for HPD 8), 8 hrs post morning dose on Day 14 |
|
|
|
| Primary | Change From Baseline in QT Interval at 12 Hour Post Morning Dose (HPD 12) on Day 14 | Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles.For each scheduled HPD, except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD. | Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. | Posted | Mean | Standard Deviation | msec | 12 hrs prior to morning dose on Day 1 (Baseline for HPD 12), 12 hrs post morning dose on Day 14 |
|
|
|
| Primary | Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval | Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum increase from baseline of 30 to less than (<) 60 msec(borderline) and greater than or equal to (>=) 60 msec (prolonged) were summarized. | Analysis population included all participants who met the eligibility criteria. | Posted | Number | participants | 1, 2, 4, 8, 12 hrs post dose, additional 16 hrs post dose for 60 mg once daily group on Day 1; 1, 2 hrs post dose on Day 4, 7, 10;1,2,4,8,12 hrs post dose on Day 14; Day 21 |
|
|
|
| Primary | Number of Participants With Corrected QT (QTc) Interval Greater Than or Equal to 500 Millisecond | Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum QTc >=500 msec were reported. | Analysis population included all participants who met the eligibility criteria. | Posted | Number | participants | 1, 2, 4, 8, 12 hrs post dose, additional 16 hrs post dose for 60 mg once daily group on Day 1; 1, 2 hrs post dose on Day 4, 7, 10;1,2,4,8,12 hrs post dose on Day 14; Day 21 |
|
|
|
| Primary | Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 1 | AUCtau = area under the curve from time zero to end of dosing interval. | Pharmacokinetic analysis population included all participants who met the eligibility criteria and had 1 post-baseline pharmacokinetic assessment. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. | Posted | Mean | Standard Deviation | nanogram*hour/milliliter (ng*hr/mL) | 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1 |
|
|
|
| Primary | Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 14 | AUCtau = area under the curve from time zero to end of dosing interval. | Pharmacokinetic analysis population included all participants who met the eligibility criteria and had 1 post-baseline pharmacokinetic assessment. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. | Posted | Mean | Standard Deviation | ng*hr/mL | 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 14 |
|
|
|
| Primary | Maximum Observed Plasma Concentration (Cmax) at Day 1 | Pharmacokinetic analysis population included all participants who met the eligibility criteria and had 1 post-baseline pharmacokinetic assessment. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. | Posted | Mean | Standard Deviation | nanogram/milliliter (ng/mL) | 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1 |
|
|
|
| Primary | Maximum Observed Plasma Concentration (Cmax) at Day 14 | Pharmacokinetic analysis population included all participants who met the eligibility criteria and had 1 post-baseline pharmacokinetic assessment. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. | Posted | Mean | Standard Deviation | ng/mL | 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 14 |
|
|
|
| Primary | Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 1 | Pharmacokinetic analysis population included all participants who met the eligibility criteria and had 1 post-baseline pharmacokinetic assessment. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. | Posted | Median | Full Range | hr | 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1 |
|
|
|
| Primary | Time to Reach Maximum Observed Plasma Concentration (Tmax) at Day 14 | Pharmacokinetic analysis population included all participants who met the eligibility criteria and had 1 post-baseline pharmacokinetic assessment. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. | Posted | Median | Full Range | hr | 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 14 |
|
|
|
| Primary | Accumulation Ratio (R0) | Accumulation ratio was calculated as, R0 = area under the curve from time zero to end of dosing interval (AUCtau) on Day 14 divided by area under the curve from time zero to end of dosing interval (AUCtau) on Day 1. | Pharmacokinetic analysis population included all participants who met the eligibility criteria and had 1 post-baseline pharmacokinetic assessment. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. | Posted | Mean | Standard Deviation | Ratio | 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12 hrs post dose on Day 1 and Day 14 |
|
|
|
| Primary | Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 1 | Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1. | Analysis population included all participants who met the eligibility criteria. | Posted | Mean | Standard Deviation | percent change | Baseline, 1 hr post-dose on Day 1 |
|
|
|
| Primary | Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 2 | Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1. | Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed)=participants evaluable for this measure. | Posted | Mean | Standard Deviation | percent change | Baseline, hr 0 on Day 2 |
|
|
|
| Primary | Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 4 | Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1. | Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed)=participants evaluable for this measure. | Posted | Mean | Standard Deviation | percent change | Baseline, hr 0 on Day 4 |
|
|
|
| Primary | Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 7 | Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1. | Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed)=participants evaluable for this measure. | Posted | Mean | Standard Deviation | percent change | Baseline, hr 0 on Day 7 |
|
|
|
| Primary | Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 10 | Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1. | Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed)=participants evaluable for this measure. | Posted | Mean | Standard Deviation | percent change | Baseline, hr 0 on Day 10 |
|
|
|
| Primary | Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 14 | Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1. | Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed)=participants evaluable for this measure. | Posted | Mean | Standard Deviation | percent change | Baseline; hr 0, 8 hr post-dose on Day 14 |
|
|
|
| Primary | Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 18 | Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1. | Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed)=participants evaluable for this measure. | Posted | Mean | Standard Deviation | percent change | Baseline, Hour 0 on Day 18 |
|
|
|
| Primary | Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 21 | Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1. | Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed)=participants evaluable for this measure. | Posted | Mean | Standard Deviation | percent change | Baseline, hr 0 on Day 21 |
|
|
|
| Primary | Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 28 | Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1. | Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed)=participants evaluable for this measure. | Posted | Mean | Standard Deviation | percent change | Baseline, hr 0 on Day 28 |
|
|
|
| Primary | Percent Change From Baseline in Fluorescence-Activated Cell Sorting (FACS) Analysis at Day 42 | Absolute cell counts of cluster of differentiation 3 (CD3): T lymphocytes, cluster of differentiation 4 (CD4): Helper/Inducer T- Lymphocytes reactive with Major Histocompatability Complex-II (MHC-II), and cluster of differentiation 8 (CD8): Suppressor/Cytotoxic T-lymphocyte reactive with Major Histocompatability Complex-I (MHC-I), cluster of differentiation 16/56 (CD16/56): natural killer Cells, cluster of differentiation 19 (CD19): B-Lymphocytes determined using FACS.Baseline defined as mean of samples collected during screening, visit in which biopsy was taken, at Day 0 and at 0 hour Day 1. | Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed)=participants evaluable for this measure. | Posted | Mean | Standard Deviation | percent change | Baseline, hr 0 on Day 42 |
|
|
|
| Primary | Change From Baseline in Immune Cell Function at Day 14 | The degree of immunosuppression induced by the study drug administration was evaluated using a bioluminescent assay in which the concentration of Adenosine-5-Triphosphate (ATP) released by CD4 cells was measured. ATP concentrations released from stimulated and unstimulated cells were evaluated. ATP Concentration less than or equal to (<=) 225: low immune cell response, 226 to 524: Moderate immune cell response, >= 525: strong immune cell response. Baseline was defined as the mean of the samples collected during the pre-dose biopsy. | Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed)=participants evaluable for this measure. 'n' = participants evaluable for this measure at specified time points for each arm group respectively. | Posted | Mean | Standard Deviation | ng/mL | Baseline (Within 7 days prior to Day 1), Day 14 |
|
|
|
| Primary | Change From Baseline in Reticulocyte Count at Day 2 | Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis. | Analysis population included all participants who met the eligibility criteria. 'n' = participants evaluable for this measure at specified time points for each arm group respectively. | Posted | Mean | Standard Deviation | 1000 cells/cubic millimeter (cells/mm^3) | Baseline (Within 7 days prior to Day 1), Day 2 |
|
|
|
| Primary | Change From Baseline in Reticulocyte Count at Day 4 | Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis. | Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. | Posted | Mean | Standard Deviation | 1000 cells/mm^3 | Baseline (Within 7 days prior to Day 1), Day 4 |
|
|
|
| Primary | Change From Baseline in Reticulocyte Count at Day 7 | Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis. | Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. | Posted | Mean | Standard Deviation | 1000 cells/mm^3 | Baseline (Within 7 days prior to Day 1), Day 7 |
|
|
|
| Primary | Change From Baseline in Reticulocyte Count at Day 10 | Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis. | Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. | Posted | Mean | Standard Deviation | 1000 cells/mm^3 | Baseline (Within 7 days prior to Day 1), Day 10 |
|
|
|
| Primary | Change From Baseline in Reticulocyte Count at Day 15 | Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis. | Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. | Posted | Mean | Standard Deviation | 1000 cells/mm^3 | Baseline (Within 7 days prior to Day 1), Day 15 |
|
|
|
| Primary | Change From Baseline in Reticulocyte Count at Day 21 | Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis. | Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. | Posted | Mean | Standard Deviation | 1000 cells/mm^3 | Baseline (Within 7 days prior to Day 1), Day 21 |
|
|
|
| Primary | Change From Baseline in Reticulocyte Count at Day 28 | Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis. | Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. | Posted | Mean | Standard Deviation | 1000 cells/mm^3 | Baseline (Within 7 days prior to Day 1), Day 28 |
|
|
|
| Primary | Change From Baseline in Reticulocyte Count at Day 42 | Reticulocyte count was assessed to detect potential of Janus kinase 2 (JAK2) mediated erythropoiesis. | Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. | Posted | Mean | Standard Deviation | 1000 cells/mm^3 | Baseline (Within 7 days prior to Day 1), Day 42 |
|
|
|
| Primary | Time to Reach Maximum Change From Baseline and Time to Return to Baseline Value for Fluorescence-Activated Cell Sorting (FACS), Reticulocyte Counts and Immune Cell Function | Data was not analyzed as per planned analyses due to pattern of changes observed. | Posted | Day 0 (pre-dose), 1, 2, 4, 7, 10, 14, 15, 18, 21, 28, 42 |
|
|
| Primary | Half Maximal Effective Area Under the Concentration-Time Curve 50 (EAUC 50) | EAUC 50 was calculated from a regression analyses using area under the concentration-time curve (AUC) as the independent variable. A sigmoid maximum effect (Emax) model was used to explain the relationship between AUC and modified Psoriasis Severity Index (mPASI) score, where Emax was the maximum effect (100 percent reduction in the total mPASI score from baseline), and EAUC 50 was the AUC where 50 percent of the maximum effect was measured. | Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. | Posted | Number | ng*hr/mL | Day 14 |
|
|
|
| Secondary | Number of Participants With Modified Psoriasis Severity Index (mPASI) at Day 14 | Modified Psoriasis Area and Severity Index (mPASI) assessed lesion severity but not the body surface area affected. Severity was estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final mPASI = sum of the each component scores. Total score range 0-12 , higher score indicated more severity. | Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed)=participants evaluable for this measure. | Posted | Number | participants | Baseline (Within 7 days prior to Day 1) up to Day 14 |
|
|
|
| Secondary | Number of Participants With Physician's Global Assessment (PGA) of Psoriasis | Physician global assessment (PGA) of Psoriasis is a 7-point scale used to assess severity of psoriatic plaques, scaling and/or erythema. Severity scale ranged from 1 to 7: 1=severe, 2=moderate to severe, 3=moderate, 4=mild to moderate, 5=mild, 6=almost clear, 7=clear (no sign of psoriasis). | Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed)=participants evaluable for this measure. | Posted | Number | participants | Baseline (Within 7 days prior to Day 1) up to Day 14 |
|
|
|
| Secondary | Gene Expression in Psoriatic Plaque Biopsies | Gene expression by quantitative polymerized chain reaction (PCR) using standard curve (SC) method generated by linear regression using log threshold cycle versus log(cell number). Keratin (K)-16, inducible nitric oxide synthase (iNOS), Interleukin 8 (IL-8), CD25, Granzyme B, IL-2, IL-7, IL-15, Interferon-gamma (INF-gamma), C-X-C motif chemokine(CXCL10), perforin 1, B-cell Lymphoma 2 (BCL-2), BCL2 associated X Protein (BAX), Tumor Necrosis Factor Fas Ligand (TNF-FasL), and proliferating cell nuclear antigen (PCNA) presented as control gene normalized expression (relative expression) within SC. | Analysis population:all participants who met eligibility criteria. 'N'(number of participants analyzed)=participants evaluable for this measure. 'n =participants evaluable for specified category for each arm group respectively. Gene expression results were planned to be analyzed for participants who received CP-690,550 5,30 mg and matching placebo. | Posted | Mean | Standard Deviation | relative expression unit (REU) | Day 14 |
|
|
|
| Secondary | Immunohistochemistry From Psoriatic Plaque Biopsies | Immunohistochemical staining of skin biopsies was performed with monoclonal antibodies directed against cluster of differentiation 3 (CD3) and cluster of differentiation 8 (CD8) T-lymphocytes, cluster of differentiation 16/56 (CD16/56) natural killer cells, and cluster of differentiation 83 (CD83) mature dendritic cells. Baseline was defined as mean of samples obtained at the screening visit within 7 days prior to Day 1, at the baseline biopsy, and Day 0. Immunohistochemistry results were planned to be analyzed for participants who received CP-690,550 5, 20, 30 mg and matching placebo. | Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed)=participants evaluable for this measure. 'n' = participants evaluable for this measure at specified time points for each arm group respectively. | Posted | Mean | Standard Deviation | cells/microliter (cells/μL) | Baseline (within 7 days prior to Day 1), Day 14 |
|
|
|
| Secondary | Number of Participants With Keratin 16 (K16) Expression | Immunohistochemical staining of skin biopsies was performed with monoclonal antibodies directed against K16. Number of participants with K16 expression were assessed qualitatively using suprabasal keratinocytes. | Analysis population included all participants who met the eligibility criteria. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure. | Posted | Number | participants | Baseline (within 7 days prior to Day 1) up to Day 14 |
|
|
|
| Secondary | Number of Participants With Intracellular Adhesion Molecule (ICAM-1) by Epidermal Keratinocytes Expression | Immunohistochemical staining of skin biopsies was performed with monoclonal antibodies directed against ICAM-1. Number of participants with ICAM-1 expression was to be assessed qualitatively using epidermal keratinocytes. | Analysis of ICAM-1 in biopsy specimens was not performed as it often continues to be expressed on vessels in the skin even when psoriasis was resolved, thus would not provide a measure of response to therapy. | Posted | Baseline (within 7 days prior to Day 1) up to Day 14 |
|
|
| Secondary | Gene Expression in Peripheral Blood | Punch biopsy and serum blood were assayed for messenger Ribonucleic acid (mRNA) gene expression by quantitative PCR using standard curve(SC) method generated by linear regression using log threshold cycle versus log(cell number). granzyme B, IFN-gamma, TNF-alpha (FasL and superfamily member 5 [SF5]), BCL2, BAX, iNOS, and CD 25 presented as control gene normalized expression(relative expression) within SC. The Relative mRNA Gene Expression Level is relative to baseline and normalized to the housekeeping gene 18 Svedberg unit ribosomal RNA (18S rRNA). | Analysis population:all participants who met eligibility criteria. 'N'(number of participants analyzed)=participants evaluable for this measure. 'n =participants evaluable for specified category for each arm group respectively. Gene expression results were planned to be analyzed for participants who received CP-690,550 5,30 mg and matching placebo. | Posted | Mean | Standard Deviation | relative expression unit (REU) | Day 14 |
|
|
|
| 0 |
| 5 |
| 0 |
| 5 |
| EG001 | CP-690,550 10 mg (Cohort 2) | CP-690,550 10 mg OPC twice daily for 13 days and single oral dose on Day 14. | 1 | 5 | 1 | 5 |
| EG002 | CP-690,550 20 mg (Cohort 3) | CP-690,550 20 mg OPC twice daily for 13 days and single oral dose on Day 14. | 0 | 10 | 3 | 10 |
| EG003 | CP-690,550 30 mg (Cohort 4) | CP-690,550 30 mg OPC twice daily for 13 days and single oral dose on Day 14. | 0 | 9 | 1 | 9 |
| EG004 | CP-690,550 60 mg (Cohort 5) | CP-690,550 60 mg tablets orally once daily up to Day 14. | 0 | 9 | 2 | 9 |
| EG005 | CP-690,550 50 mg (Cohort 6) | CP-690,550 50 mg tablets orally twice daily for 13 days and single oral dose on Day 14. | 0 | 8 | 2 | 8 |
| EG006 | Placebo | Placebo matched to CP-690,550 for 13 days and single oral dose on Day 14. | 0 | 13 | 2 | 13 |
| Lab test abnormal | General disorders | COSTART | Non-systematic Assessment |
|
| Nausea | Gastrointestinal disorders | COSTART | Non-systematic Assessment |
|
| Peripheral edema | Metabolism and nutrition disorders | COSTART | Non-systematic Assessment |
|
| SGOT increased | Metabolism and nutrition disorders | COSTART | Non-systematic Assessment |
|
| SGPT increased | Metabolism and nutrition disorders | COSTART | Non-systematic Assessment |
|
| Arthrosis | Musculoskeletal and connective tissue disorders | COSTART | Non-systematic Assessment |
|
| Insomnia | Nervous system disorders | COSTART | Non-systematic Assessment |
|
| Psoriasis | Skin and subcutaneous tissue disorders | COSTART | Non-systematic Assessment |
|
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
| D013568 | Pathological Conditions, Signs and Symptoms |
| Change at HPD 2 on Day 1 |
|
| Change at HPD 4 on Day 1 (n=5,5,9,9,9,8,13) |
|
| Change at HPD 8 on Day 1 (n=5,5,9,9,9,8,13) |
|
| Change at HPD 12 on Day 1 (n=5,5,9,9,9,8,13) |
|
| Change at HPD 0 on Day 14 |
|
| QTcB,Maximum increase from baseline:>=60msec |
|
| QTcF,Maximum increase from baseline:30 to <60msec |
|
| QTcF,Maximum increase from baseline:>=60msec |
|
| QTcF |
|
| Change at Day 1: CD4 |
|
| Change at Day 1: CD8 |
|
| Change at Day 1: CD16/56 |
|
| Change at Day 1: CD19 |
|
| Change at Day 2: CD4 |
|
| Change at Day 2: CD8 |
|
| Change at Day 2: CD16/56 |
|
| Change at Day 2: CD19 |
|
| Change at Day 4: CD4 |
|
| Change at Day 4: CD8 |
|
| Change at Day 4: CD16/56 |
|
| Change at Day 4: CD19 |
|
| Change at Day 7: CD4 |
|
| Change at Day 7: CD8 |
|
| Change at Day 7: CD16/56 |
|
| Change at Day 7: CD19 |
|
| Change at Day 10: CD4 |
|
| Change at Day 10: CD8 |
|
| Change at Day 10: CD16/56 |
|
| Change at Day 10: CD19 |
|
| Change at 8 hr post dose on Day 14: CD3 |
|
| Change at 0 hr post dose on Day 14: CD4 |
|
| Change at 8 hr post dose on Day 14: CD4 |
|
| Change at 0 hr post dose on Day 14: CD8 |
|
| Change at 8 hr post dose on Day 14: CD8 |
|
| Change at 0 hr post dose on Day 14: CD16/56 |
|
| Change at 8 hr post dose on Day 14: CD16/56 |
|
| Change at 0 hr post dose on Day 14: CD19 |
|
| Change at 8 hr post dose on Day 14: CD19 |
|
| Change at Day 18: CD4 |
|
| Change at Day 18: CD8 |
|
| Change at Day 18: CD16/56 |
|
| Change at Day 18: CD19 |
|
| Change at Day 21: CD4 |
|
| Change at Day 21: CD8 |
|
| Change at Day 21: CD16/56 |
|
| Change at Day 21: CD19 |
|
| Change at Day 28: CD4 |
|
| Change at Day 28: CD8 |
|
| Change at Day 28: CD16/56 |
|
| Change at Day 28: CD19 |
|
| Change at Day 42: CD4 |
|
| Change at Day 42: CD8 |
|
| Change at Day 42: CD16/56 |
|
| Change at Day 42: CD19 |
|
| Baseline: Unstimulated(Uns) ATP(n=2,5,10,9,9,7,13) |
|
| Change at Day 14: Stimulated ATP(n=2,5,9,9,9,7,13) |
|
| Change at Day 14:Uns ATP(n=2,5,9,9,9,7,13) |
|
| Change at Day 2 (n=5,5,9,9,8,8,12) |
|
| Erythema: 1 |
|
| Erythema: 2 |
|
| Erythema: 3 |
|
| Erythema: 4 |
|
| Induration: 0 |
|
| Induration: 1 |
|
| Induration: 2 |
|
| Induration: 3 |
|
| Induration: 4 |
|
| Scaling: 0 |
|
| Scaling: 1 |
|
| Scaling: 2 |
|
| Scaling: 3 |
|
| Scaling: 4 |
|
| PGA:2 |
|
| PGA:3 |
|
| PGA:4 |
|
| PGA:5 |
|
| PGA:6 |
|
| PGA:7 |
|
| BAX |
|
| CD25 |
|
| CXCL10 |
|
| Granzyme B |
|
| IL-2 |
|
| IL-8 |
|
| INOS |
|
| INF-gamma |
|
| IL-15 |
|
| IL-7 |
|
| K-16 |
|
| PCNA |
|
| Perforin |
|
| TNF-FasL |
|
| Baseline: CD3 dermal (n=1,1,4,2) |
|
| Baseline: CD8 epidermal (n=1,1,4,2) |
|
| Baseline: CD8 dermal (n=1,1,4,2) |
|
| Baseline: CD83 epidermal (n=1,1,4,2) |
|
| Baseline: CD83 dermal (n=1,1,4,2) |
|
| Baseline: Absolute CD16/56 (n=0,0,0,0) |
|
| Day 14: CD3 epidermal (n=1,1,4,2) |
|
| Day 14: CD3 dermal (n=1,1,4,2) |
|
| Day 14: CD8 epidermal (n=1,1,4,2) |
|
| Day 14: CD8 dermal (n=1,1,4,2) |
|
| Day 14: CD83 epidermal (n=1,1,4,2) |
|
| Day 14: CD83 dermal (n=1,1,4,2) |
|
| Day 14: Absolute CD16/56 (n=0,0,0,0) |
|
| Day 14 |
|
|
| TNF-SF5 (n=9,9,6) |
|
| TNF-FasL (n=9,9,6) |
|
| BCL2 (n=9,9,6) |
|
| BAX (n=9,9,6) |
|
| iNOS (n=2,1,1) |
|
| CD 25 (n=9,9,6) |
|